WOODBURY, N.Y., Nov. 25, 2015 /PRNewswire/ -- Linden Care, LLC, a retail specialty pharmacy focused on medications access and optimizing treatment outcomes for patients suffering from chronic pain, said today that it is disappointed that its request for a Temporary Restraining Order (TRO) enjoining Express Scripts from unilaterally terminating the Pharmacy Provider Agreement between the two companies has been rejected.
The company said that it is aggressively pursuing all of its legal options.
In the meantime, the company stressed that many of the drugs dispensed by Linden Care are highly regulated and controlled medications not readily available at most retail pharmacies. A key example is a class of drugs based on fentanyl, which is 100 times more potent than morphine. Linden Care is specially equipped to help patients who require this medication under a program approved by the FDA.
Given the extreme needs of patients who require these medications, Linden Care has continued to provide these medications to members-in-need to prevent adverse patient outcomes.
Marc Wiener, Linden Care CEO, said, "We are disappointed in this ruling and believe we will prevail in arbitration proceedings. We are, and always have been, an independent specialty pharmacy under no manufacturer ownership or influence. Our work is critical to those in need."
About Linden Care
Headquartered in Woodbury, NY, Linden Care is a leading provider of specialty pharmacy services to the pain management industry. The Company is licensed in all 50 states and serves patients and physicians in the highly regulated pain industry. With best-in-class compliance practices, Linden Care works closely with leading pain pharmaceutical manufacturers and pain management physicians to facilitate medication access and optimize treatment outcomes for patients suffering from chronic pain.
SOURCE Linden Care, LLC